The Tumor Microenvironment of DLBCL in the Computational Era

被引:26
作者
Opinto, Giuseppina [1 ]
Vegliante, Maria Carmela [1 ]
Negri, Antonio [1 ]
Skrypets, Tetiana [1 ,2 ]
Loseto, Giacomo [1 ]
Pileri, Stefano Aldo [3 ]
Guarini, Attilio [1 ]
Ciavarella, Sabino [1 ]
机构
[1] Ist Tumori Giovanni Paolo II IIIRCCS, Unit Hematol & Cell Therapy, Lab Hematol Diagnost & Cell Characterizat, Bari, Italy
[2] Univ Modena & Reggio Emilia, CHIMOMO Dept, Modena, Italy
[3] European Inst Oncol IRCCS, Div Haematopathol, Milan, Italy
来源
FRONTIERS IN ONCOLOGY | 2020年 / 10卷
关键词
tumor microenvironment; transcriptomics; deconvolution; prognostication; DLBCL; B-CELL LYMPHOMA; PROGNOSTIC-FACTORS; GENE-EXPRESSION; MACROPHAGES; SURVIVAL; ACTIVATION; SUBTYPES; STROMA; NODE;
D O I
10.3389/fonc.2020.00351
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Among classical exemplifications of tumor microenvironment (TME) in lymphoma pathogenesis, the "effacement model" resembled by diffuse large B cell lymphoma (DLBCL) implies strong cell autonomous survival and paucity of non-malignant elements. Nonetheless, the magnitude of TME exploration is increasing as novel technologies allow the high-resolution discrimination of cellular and extra-cellular determinants at the functional, more than morphological, level. Results from genomic-scale studies and recent clinical trials revitalized the interest in this field, prompting the use of new tools to dissect DLBCL composition and reveal novel prognostic association. Here we revisited major controversies related to TME in DLBCL, focusing on the use of bioinformatics to mine transcriptomic data and provide new insights to be translated into the clinical setting.
引用
收藏
页数:7
相关论文
共 57 条
  • [1] CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
    Advani, Ranjana
    Flinn, Ian
    Popplewell, Leslie
    Forero, Andres
    Bartlett, Nancy L.
    Ghosh, Nilanjan
    Kline, Justin
    Roschewski, Mark
    LaCasce, Ann
    Collins, Graham P.
    Thu Tran
    Lynn, Judith
    Chen, James Y.
    Volkmer, Jens-Peter
    Agoram, Balaji
    Huang, Jie
    Majeti, Ravindra
    Weissman, Irving L.
    Takimoto, Chris H.
    Chao, Mark P.
    Smith, Sonali M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (18) : 1711 - 1721
  • [2] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [3] [Anonymous], ATLAS CLIN DISTINCT
  • [4] [Anonymous], WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Internet. Geneva: WHO Press
  • [5] 2008
  • [6] [Anonymous], MICROENVIRONMENTAL S
  • [7] Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
    Ansell, Stephen M.
    Minnema, Monique C.
    Johnson, Peter
    Timmerman, John M.
    Armand, Philippe
    Shipp, Margaret A.
    Rodig, Scott J.
    Ligon, Azra H.
    Roemer, Margaretha G. M.
    Reddy, Nishitha
    Cohen, Jonathon B.
    Assouline, Sarit
    Poon, Michelle
    Sharma, Manish
    Kato, Kazunobu
    Samakoglu, Selda
    Sumbul, Anne
    Grigg, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (06) : 481 - +
  • [8] Diffuse Large B-Cell Lymphoma Remodels the Fibroblastic Reticular Network That Acquires Aberrant Immunosuppressive Capabilities; Implications for the Regulation of Anti-Tumor Immunity in the Immuno-Oncology Era
    Apollonio, Benedetta
    Jarvis, Peter
    Phillips, Beth
    Kuhnl, Andrea
    Salisbury, Jon
    Zacharioudakis, Georgios
    Sutton, Lesley-Ann
    Rosenquist, Richard
    Jarrett, Ruth
    Amini, Rose-Marie
    Vardi, Anna
    Ramsay, Alan G.
    [J]. BLOOD, 2018, 132
  • [9] The combined expression of the stromal markers fibronectin and SPARC improves the prediction of survival in diffuse large B-cell lymphoma
    Brandt S.
    Montagna C.
    Georgis A.
    Schüffler P.J.
    Bühler M.M.
    Seifert B.
    Thiesler T.
    Curioni-Fontecedro A.
    Hegyi I.
    Dehler S.
    Martin V.
    Tinguely M.
    Soldini D.
    [J]. Experimental Hematology & Oncology, 2 (1)
  • [10] Cacciatore Matilde, 2012, Adv Hematol, V2012, P138079, DOI 10.1155/2012/138079